BR112017007708B8 - Composto macrocíclico e composição farmacêutica - Google Patents
Composto macrocíclico e composição farmacêuticaInfo
- Publication number
- BR112017007708B8 BR112017007708B8 BR112017007708A BR112017007708A BR112017007708B8 BR 112017007708 B8 BR112017007708 B8 BR 112017007708B8 BR 112017007708 A BR112017007708 A BR 112017007708A BR 112017007708 A BR112017007708 A BR 112017007708A BR 112017007708 B8 BR112017007708 B8 BR 112017007708B8
- Authority
- BR
- Brazil
- Prior art keywords
- macrocyclic compound
- pharmaceutical composition
- group
- sulfur
- nitrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063176P | 2014-10-13 | 2014-10-13 | |
| US62/063,176 | 2014-10-13 | ||
| US201562104274P | 2015-01-16 | 2015-01-16 | |
| US62/104,274 | 2015-01-16 | ||
| PCT/US2015/055317 WO2016061097A1 (en) | 2014-10-13 | 2015-10-13 | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR112017007708A2 BR112017007708A2 (pt) | 2017-12-19 |
| BR112017007708A8 BR112017007708A8 (enExample) | 2017-12-19 |
| BR112017007708B1 BR112017007708B1 (pt) | 2023-07-25 |
| BR112017007708B8 true BR112017007708B8 (pt) | 2023-10-24 |
Family
ID=55654998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017007708A BR112017007708B8 (pt) | 2014-10-13 | 2015-10-13 | Composto macrocíclico e composição farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9663535B2 (enExample) |
| EP (1) | EP3207031B1 (enExample) |
| JP (1) | JP6678679B2 (enExample) |
| KR (1) | KR102569226B1 (enExample) |
| CN (1) | CN107108527B (enExample) |
| AU (1) | AU2015333738B2 (enExample) |
| BR (1) | BR112017007708B8 (enExample) |
| CA (1) | CA2963973C (enExample) |
| ES (1) | ES2879441T3 (enExample) |
| IL (1) | IL251595B (enExample) |
| MX (1) | MX389198B (enExample) |
| WO (1) | WO2016061097A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017007708B8 (pt) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Composto macrocíclico e composição farmacêutica |
| WO2017180723A1 (en) * | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use |
| EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| SMT202400106T1 (it) | 2017-07-13 | 2024-05-14 | Univ Texas | Inibitori eterociclici della atr chinasi |
| EP3668839B1 (en) | 2017-08-17 | 2023-04-12 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
| WO2019055657A1 (en) * | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | BAF COMPLEX MODULATION COMPOUNDS AND METHODS OF USE |
| CN112218631B (zh) | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
| CN110357905B (zh) * | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
| EP3820460A1 (en) | 2018-07-12 | 2021-05-19 | The Board of Trustees of the Leland Stanford Junior University | Methods for reversing hiv latency using baf complex modulating compounds |
| CN110950890B (zh) * | 2018-09-27 | 2022-07-01 | 北京赛林泰医药技术有限公司 | 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂 |
| MX2021005012A (es) | 2018-10-30 | 2021-07-21 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr. |
| CN114369096A (zh) | 2020-10-16 | 2022-04-19 | 上海迪诺医药科技有限公司 | 三杂环衍生物、其药物组合物及应用 |
| WO2023201320A1 (en) | 2022-04-14 | 2023-10-19 | Atrin Pharmaceuticals LLC | Atr inhibitors |
| CN119317434A (zh) | 2022-06-15 | 2025-01-14 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| WO2025181153A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230098B2 (en) * | 2003-02-26 | 2007-06-12 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| EP2376485B1 (en) | 2008-12-19 | 2017-12-06 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| JP2013526540A (ja) * | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2012125603A1 (en) * | 2011-03-16 | 2012-09-20 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
| ES2621220T3 (es) * | 2012-03-06 | 2017-07-03 | Pfizer Inc. | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas |
| WO2013139697A1 (en) * | 2012-03-17 | 2013-09-26 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| BR112017007708B8 (pt) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Composto macrocíclico e composição farmacêutica |
-
2015
- 2015-10-13 BR BR112017007708A patent/BR112017007708B8/pt active Search and Examination
- 2015-10-13 JP JP2017538930A patent/JP6678679B2/ja active Active
- 2015-10-13 AU AU2015333738A patent/AU2015333738B2/en active Active
- 2015-10-13 WO PCT/US2015/055317 patent/WO2016061097A1/en not_active Ceased
- 2015-10-13 CN CN201580067182.7A patent/CN107108527B/zh active Active
- 2015-10-13 MX MX2017004515A patent/MX389198B/es unknown
- 2015-10-13 CA CA2963973A patent/CA2963973C/en active Active
- 2015-10-13 KR KR1020177012838A patent/KR102569226B1/ko active Active
- 2015-10-13 ES ES15850553T patent/ES2879441T3/es active Active
- 2015-10-13 US US14/881,680 patent/US9663535B2/en active Active
- 2015-10-13 EP EP15850553.7A patent/EP3207031B1/en active Active
-
2017
- 2017-04-05 IL IL251595A patent/IL251595B/en unknown
- 2017-04-27 US US15/498,631 patent/US9981989B2/en active Active
-
2018
- 2018-04-12 US US15/951,302 patent/US10196405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6678679B2 (ja) | 2020-04-08 |
| BR112017007708A2 (pt) | 2017-12-19 |
| BR112017007708A8 (enExample) | 2017-12-19 |
| KR20170082532A (ko) | 2017-07-14 |
| WO2016061097A1 (en) | 2016-04-21 |
| MX2017004515A (es) | 2017-10-31 |
| US9981989B2 (en) | 2018-05-29 |
| IL251595A0 (en) | 2017-06-29 |
| ES2879441T3 (es) | 2021-11-22 |
| EP3207031A4 (en) | 2018-02-14 |
| BR112017007708B1 (pt) | 2023-07-25 |
| AU2015333738A1 (en) | 2017-05-04 |
| US20170226130A1 (en) | 2017-08-10 |
| CN107108527A (zh) | 2017-08-29 |
| US9663535B2 (en) | 2017-05-30 |
| US20160102104A1 (en) | 2016-04-14 |
| CA2963973A1 (en) | 2016-04-21 |
| AU2015333738B2 (en) | 2020-03-26 |
| CN107108527B (zh) | 2022-08-02 |
| MX389198B (es) | 2025-03-20 |
| JP2017531041A (ja) | 2017-10-19 |
| EP3207031B1 (en) | 2021-04-14 |
| KR102569226B1 (ko) | 2023-08-22 |
| EP3207031A1 (en) | 2017-08-23 |
| IL251595B (en) | 2022-04-01 |
| CA2963973C (en) | 2023-01-10 |
| US10196405B2 (en) | 2019-02-05 |
| US20180230168A1 (en) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017007708B8 (pt) | Composto macrocíclico e composição farmacêutica | |
| CY1123801T1 (el) | Παραγωγα αρωματικου σουλφοναμιδιου | |
| CL2021000387A1 (es) | Compuestos de anillo fusionado | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| EA201692010A1 (ru) | Фармацевтическое соединение | |
| BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
| BR112019000247A2 (pt) | derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| DOP2017000176A (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
| EA201892838A1 (ru) | Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их | |
| BR112017013677A2 (pt) | compostos macrocíclicos como inibidores de irak1/4 e usos dos mesmos | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| BR112018016196A2 (pt) | derivados do dióxido de iminotiadiazinano como inibidores da plasmepsina v | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| IL284159A (en) | Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof | |
| EA201692270A1 (ru) | Производные нафтиридиндиона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 241/04 Ipc: A61K 31/4985 (2006.01), A61K 31/5377 (2006.01), A6 |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
| B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFIQUE-SE PARA CORRECAO DE ERROS DE DIGITACAO APONTADOS PELA REQUERENTE. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2742 DE 25/07/2023, QUANTO AO QUADRO REIVINDICATORIO. |